S66 Dec 2024 Half Year Report & Financial Statements

• Core manufacturing and distribution business grew 37% to $14.6 million
• OEM division revenue up 50% to $11.3 million
• Retail division revenue declined 28.5% to $1.1 million

Star Combo Pharma Ltd reported a strong financial performance for the 1H FY25, with group revenue increasing 28.8% to $16.03 million. The core manufacturing and distribution business grew 37.1% to $14.64 million, underpinned by an expansion of the client base and the development of new products. The OEM division continued its strong momentum, with revenue increasing 50% to $11.29 million. However, the retail division, comprising the Austoyou and Koala Mall businesses, saw a 28.5% decline in revenue to $1.11 million. Overall, the Group reported a 120% increase in operating profit after tax to $276,342. There were no significant changes in the state of affairs during the period, and the Directors did not declare a dividend. Looking ahead, the Group's focus remains on growing its contract manufacturing operations, commissioning additional manufacturing capacity, and restoring revenues and operational efficiencies in its retail division.

The Group did not provide any high-importance, price-sensitive forward-looking financial metrics in the announcement.

The Group's business strategy in FY25 remains focused on growing its contract manufacturing operations, successfully commissioning additional manufacturing capacity at Smithfield, and restoring revenues and operational efficiencies in its retail division.